Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma: An Evidence Review Group Evaluation of the NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE), as part of the institute’s single technology appraisal (STA) process, invited the company that makes obinutuzumab (Roche Products Limited) to submit evidence of the clinical and cost effectiveness of the drug in combination with chemother...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacoeconomics
Main Authors: Thielen, Frederick W., Büyükkaramikli, Nasuh C., Riemsma, Rob, Fayter, Debra, Armstrong, Nigel, Wei, Ching-Yun, Huertas Carrera, Vanesa, Misso, Kate, Worthy, Gill, Kleijnen, Jos, Corro Ramos, Isaac
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2018
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6598743/
https://ncbi.nlm.nih.gov/pubmed/30547368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-018-0740-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados